Pre- and Intra-operative Intravitreal Bevacizumab Injection in Diabetic Vitrectomy

• Status: Completed
• Trial end date: 2010-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effect of pre- and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Bundang Hospital
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Patients undergoing first vitrectomy for complications of proliferative diabetic retinopathy such as vitreous hemorrhage, tractional fibrovascular membrane proliferation, tractional or combined retinal detachment)

Exclusion Criteria:

• Follow-up period of less than 6 months

• Intraoperative use of long-acting gas or silicone oil

• Repeat vitrectomy after first vitrectomy for diseases other than vitreous hemorrhage

• Not first vitrectomy

• Uncontrolled hypertension

• Medical history of abnormal blood coagulation

• Time interval between IVB injection and PPV longer than 2 weeks and recent history (within 3 months) of IVB treatment